Related Experiment Videos
Severe hypertriglyceridaemia and hypercholesterolaemia associated with tamoxifen use
1Christchurch Hospital, New Zealand.
Clinical Oncology (Royal College of Radiologists (Great Britain))
|October 9, 1998
Summary
Tamoxifen, used for breast cancer, can cause severe hyperlipidaemia (high blood lipids) and acute pancreatitis. Caution is advised, especially for patients with type IV hyperlipidaemia, as tamoxifen may worsen lipid levels.
Area of Science:
- Endocrinology
- Oncology
- Clinical Pharmacology
Background:
- Tamoxifen is a widely used adjuvant endocrine therapy for estrogen receptor-positive breast cancer.
- Adjuvant treatment aims to reduce the risk of cancer recurrence and improve patient survival.
- Understanding potential adverse effects is crucial for safe and effective patient management.
Observation:
- A patient undergoing adjuvant tamoxifen therapy for breast cancer experienced severe hypertriglyceridaemia and hypercholesterolaemia.
- The patient also developed acute pancreatitis after four months of tamoxifen treatment.
- These symptoms suggest a potential link between tamoxifen and severe lipid abnormalities.
Findings:
- The patient presented with symptoms indicative of type IV hyperlipidaemia.
- Discontinuation of tamoxifen and initiation of gemfibrozil treatment led to the correction of hyperlipidaemia.
- This case highlights a severe adverse reaction to tamoxifen therapy.
Implications:
- Tamoxifen's weak estrogenic effect may precipitate severe, life-threatening hyperlipidaemia in susceptible individuals.
- Patients with pre-existing lipid disorders, such as type IV hyperlipidaemia, may be at increased risk.
- Clinicians should exercise extreme caution when prescribing tamoxifen to patients with or at risk for hyperlipidaemia.